Compare ARLO & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | EYPT |
|---|---|---|
| Founded | 2018 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Staples | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | 2005 |
| Metric | ARLO | EYPT |
|---|---|---|
| Price | $13.19 | $12.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $24.00 | ★ $31.80 |
| AVG Volume (30 Days) | ★ 1.4M | 724.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.82 | $3,115.57 |
| P/E Ratio | $97.92 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.05 | $5.57 |
| 52 Week High | $19.94 | $19.11 |
| Indicator | ARLO | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 45.67 | 46.70 |
| Support Level | $11.64 | $12.66 |
| Resistance Level | $14.78 | $14.73 |
| Average True Range (ATR) | 0.78 | 0.74 |
| MACD | -0.10 | -0.05 |
| Stochastic Oscillator | 22.48 | 47.26 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.